Because SMA is a neurodegenerative disease, the iPS cells used in this experiment may be one of the better in vitro cellular models for SMA and offer further proof of concept that targeted reduction of cellular SRSF3 would result in an increase in SMN protein in a cell type that is relevant for SMA. The gene discussed is SRSF3; the disease is neurodegenerative disease.